NEW YORK, NY; NEW HAVEN, CT; and PRINCETON, NJ, March 10, 2026 (GLOBE NEWSWIRE) — Aptorum Group Limited (NASDAQ: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, and DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced the publication of a paper by Giliberto, et. al. titled “Development of microRNA-Based Glioblastoma Biomarkers Using Blood Plasma Specimens” in Diagnostics, (https://doi.org/10.3390/diagnostics16050791), a leading peer-reviewed journal focused on clinical diagnostics and biomarker research.